Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 3
1990 1
1991 4
1992 7
1993 14
1994 17
1995 28
1996 20
1997 18
1998 18
1999 10
2000 12
2001 10
2002 12
2003 7
2004 15
2005 14
2006 9
2007 5
2008 14
2009 13
2010 16
2011 12
2012 14
2013 10
2014 4
2015 10
2016 4
2017 6
2018 8
2019 10
2020 4
2021 12
2022 5
2023 8
2024 13
2025 9
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

378 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Ganciclovir as a potential treatment for glioma: a systematic review and meta-analysis.
Chang CT, Chen HH, Chuang CC, Chang SH, Hsiao NW. Chang CT, et al. J Neurooncol. 2023 Dec;165(3):399-411. doi: 10.1007/s11060-023-04503-3. Epub 2023 Dec 8. J Neurooncol. 2023. PMID: 38066255
The search terms included glioma, ganciclovir, valganciclovir and treatment. Calculated 1, 2 and 4-year survival rate by risk difference (RD), and overall survival (OS) by odds ratio (OR). ...CONCLUSIONS: This meta-analysis showed that ganciclovir significantly impr …
The search terms included glioma, ganciclovir, valganciclovir and treatment. Calculated 1, 2 and 4-year survival rate by risk differe …
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.
Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A; VICTOR Study Group. Asberg A, et al. Am J Transplant. 2007 Sep;7(9):2106-13. doi: 10.1111/j.1600-6143.2007.01910.x. Epub 2007 Jul 19. Am J Transplant. 2007. PMID: 17640310 Free article. Clinical Trial.
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. ...A total of 321 patients were evaluated (valganciclovir [n = 164]; i.v. ganciclovir [n = 157]). The success rate of viremia eradication at Day 21 wa …
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. ...A total of 321 …
Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection.
Chou S, Winston DJ, Avery RK, Cordonnier C, Duarte RF, Haider S, Maertens J, Peggs KS, Solano C, Young JH, Gu J, Pocock G, Papanicolaou GA. Chou S, et al. J Infect Dis. 2025 Mar 17;231(3):e470-e477. doi: 10.1093/infdis/jiae469. J Infect Dis. 2025. PMID: 39302855 Free PMC article. Clinical Trial.
One maribavir recipient developed a novel UL97 gene mutation (P-loop substitution G343A) that conferred strong maribavir and ganciclovir resistance in vitro. Viral clearance was confirmed in 17 (74%) of 23 patients with emergent maribavir resistance after retreatment with …
One maribavir recipient developed a novel UL97 gene mutation (P-loop substitution G343A) that conferred strong maribavir and ganciclovir …
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kamar N, Kumar D, Maertens J, Marty FM, Papanicolaou GA, Silveira FP, Witzke O, Wu J, Sundberg AK, Fournier M; SOLSTICE Trial Investigators. Avery RK, et al. Clin Infect Dis. 2022 Sep 10;75(4):690-701. doi: 10.1093/cid/ciab988. Clin Infect Dis. 2022. PMID: 34864943 Free PMC article. Clinical Trial.
METHODS: In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for …
METHODS: In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomize …
The Effect of (Val)ganciclovir on Hearing in Congenital Cytomegalovirus: A Systematic Review.
De Cuyper E, Acke F, Keymeulen A, Dhooge I. De Cuyper E, et al. Laryngoscope. 2022 Nov;132(11):2241-2250. doi: 10.1002/lary.30027. Epub 2022 Jan 24. Laryngoscope. 2022. PMID: 35072277
OBJECTIVE: To search for existing evidence of a beneficial effect of (val)ganciclovir on hearing in children with congenital cytomegalovirus (cCMV) infection and to identify future research questions. ...CONCLUSIONS: There is sufficient evidence in literature to support tr …
OBJECTIVE: To search for existing evidence of a beneficial effect of (val)ganciclovir on hearing in children with congenital cytomega …
Foscarnet Versus Ganciclovir for Severe Congenital Cytomegalovirus Infection: Short- and Long-Term Follow-Up.
Nigro G, Buzzi M, Catenaro M, Coclite E, Muselli M. Nigro G, et al. Viruses. 2025 May 17;17(5):720. doi: 10.3390/v17050720. Viruses. 2025. PMID: 40431731 Free PMC article. Clinical Trial.
STUDY DESIGN: In the 1990s, we noted that intravenous ganciclovir did not cure some children with severe sequelae due to congenital cytomegalovirus (CMV) infection. ...Neurological outcomes were normal in three of the ten children treated with foscarnet, in two of the ten …
STUDY DESIGN: In the 1990s, we noted that intravenous ganciclovir did not cure some children with severe sequelae due to congenital c …
[Ganciclovir therapy for congenital cytomegalovirus infection in newborn infants: a meta analysis].
Hu JT, Chen PY, Xie ZD, Dang XQ, Wang T, He XR, Li W, Bo T. Hu JT, et al. Zhongguo Dang Dai Er Ke Za Zhi. 2010 Jan;12(1):35-9. Zhongguo Dang Dai Er Ke Za Zhi. 2010. PMID: 20113632 Free article. Chinese.
RESULTS: Ten papers were included. Meta analysis showed that the ganciclovir therapy increased the improvement rate (91.4% vs 34.0%; p<0.01) and led CMV infection indexes to become negative in more patients (87.6% vs 15.3%; p<0.01) and decreased incidence of hearing …
RESULTS: Ten papers were included. Meta analysis showed that the ganciclovir therapy increased the improvement rate (91.4% vs 34.0%; …
Valganciclovir for symptomatic congenital cytomegalovirus disease.
Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, DeBiasi RL, Han JY, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths PD, Luck S, Gutierrez K, Halasa N, Homans J, Shane AL, Sharland M, Simonsen K, Vanchiere JA, Woods CR, Sabo DL, Aban I, Kuo H, James SH, Prichard MN, Griffin J, Giles D, Acosta EP, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Kimberlin DW, et al. N Engl J Med. 2015 Mar 5;372(10):933-43. doi: 10.1056/NEJMoa1404599. N Engl J Med. 2015. PMID: 25738669 Free PMC article. Clinical Trial.
BACKGROUND: The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time. ...
BACKGROUND: The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been s …
378 results